Topics
No topics available
Bill Information
Summary
Bill Summary
While this bill contains consumer protections (21+ age restrictions, child-resistant packaging, anti-deceptive marketing) aligned with KCPA principles, the 2% 7-OH cap doesn't distinguish between natural alkaloid content and synthetic products; it risks banning natural high-7-OH strains. FDA guidance and the research positions explicitly support distinguishing natural kratom from synthetics; this restricts alkaloid percentage regardless of source.
Why it matters to MAHA
CA AB1088 follows a flawed regulatory approach that contradicts the FDA's July 2025 guidance. Rather than targeting synthetic/concentrated 7-OH specifically, it caps all 7-OH at 2%, potentially banning natural strains that fall above this threshold. This represents health authoritarianism through alkaloid ceiling-setting rather than the transparent consumer-protection KCPA model MAHA supports, which protects against synthetics while preserving natural product access.
Introduced
02/20/2025
In Committee
06/10/2026
Crossed Over
06/02/2025
Pending
Pending
Sponsor

Jasmeet Bains
Democratic State Assemblymember (CA)